share_log

8-K: Teva Announces Strong Financial Results for the Third Quarter of 2024, led by Generics Performance and Innovative Portfolio Growth; Raises 2024 Financial Outlook including on Revenues, Adjusted EBITDA and Non-GAAP EPS

8-K: Teva Announces Strong Financial Results for the Third Quarter of 2024, led by Generics Performance and Innovative Portfolio Growth; Raises 2024 Financial Outlook including on Revenues, Adjusted EBITDA and Non-GAAP EPS

8-K:梯瓦公佈2024年第三季度強勁的財務業績,由仿製藥業績和創新投資組合增長帶動;上調了2024年財務展望,包括收入、調整後的息稅折舊攤銷前利潤和非公認會計准則每股收益
美股SEC公告 ·  11/06 07:02
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息